Collectively, this body of work builds upon our understanding of the AhR pathway in breast cancer and the chemical structures required to develop novel agents that undergo bio-activation to a cancer killing molecule in a select population of cells, while having little to no effect in other cell types including normal breast cells. The gene discussed is AHR; the disease is breast cancer.